BioSpace News Archive

BioInvent International AB announced a clinical supply agreement with AstraZeneca to evaluate BioInvent’s anti-FcyRIIB antibody, BI-1206, in combination with rituximab and Calquence®, in a Phase 1/2a study in non-Hodgkin’s lymphoma.

Senzime Senzime invites investors, analysts, and media to a webcast presentation of the fourth quarter report for 2023 on February 15, 08:30 CET.

Vicore Pharma Holding AB, unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, announced it has entered into an exclusive licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company, to develop and commercialize Vicore’s drug candidate C21 in Japan.

Centessa Pharmaceuticals plc will be presented during an oral presentation at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Frankfurt, Germany, today, February 9, 2024.

NanoString Technologies, Inc. announced the Company has entered into a credit agreement with its existing lenders comprised of $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S.

OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need The initial trial of OK-101 to treat NCP is designed as a randomized, placebo-controlled, double-masked Phase 2 clinical trial and is planned to begin in 2Q 2024 NCP is an Orphan disease as listed in the National Organization for Rare Disorders LONDON and NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE)

Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.

MaxCyte, Inc. today announced that it will release financial results for the fourth quarter and full year 2023 after the U.S. market close on Tuesday, March 12th, 2024.

Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for nipocalimab for the treatment of alloimmunizeda pregnant individuals at high risk of severe hemolytic disease of the fetus and newborn (HDFN).

Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.